The AAGAB Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population with disrupted expression of the alpha- and gamma-adaptin binding protein (AAGAB). This polyclonal knockout model is generated by CRISPR/Cas9-mediated gene disruption in the Huh-7 parental line, yielding a heterogeneous pool of loss-of-function cells that avoids clonal selection artifacts while preserving the host genetic background.
The host cell line Huh-7 is a human hepatocellular carcinoma epithelial line derived from a 57-year-old Japanese male. It is extensively utilized as a model for liver cancer biology, hepatic metabolism, and hepatitis C virus (HCV) research, owing to its permissiveness for viral replication and retention of hepatocyte-specific functions.
Molecularly, AAGAB functions as a critical cofactor in clathrin-mediated endocytosis by directly binding to alpha- and gamma-adaptin subunits of the AP-2 complex (AP2A1, AP2A2, and AP1G1). This interaction facilitates the assembly of clathrin-coated pits at the plasma membrane, downstream of EGFR ligand binding. AAGAB is essential for the efficient internalization of cargo receptors, notably EGFR and transferrin receptor, and collaborates with clathrin and dynamin to drive vesicle scission and receptor trafficking.
In the hepatocellular carcinoma context, AAGAB knockout disrupts endocytic machinery that is central to oncogenic signaling and viral pathogenesis. Altered EGFR internalization may impinge on downstream pathways driving hepatocarcinogenesis, while impaired endocytosis provides a means to interrogate HCV entry mechanisms that subvert host machinery. Additionally, this model holds relevance for punctate palmoplantar keratoderma type 1, an epithelial disorder linked to AAGAB mutations.
Key research applications include western blotting and immunofluorescence for target validation, transferrin uptake and flow cytometry-based EGFR internalization assays to measure endocytic function, and co-immunoprecipitation to assess AP-2 complex integrity. Transcriptomic profiling by RNA-seq and drug sensitivity analyses can reveal broader cellular consequences. This model is also suited for HCV entry studies and signaling investigations. For further details, researchers are encouraged to contact Ascent Research.
